Breast Cancer Research and Treatment

, Volume 49, Issue 2, pp 97–107 | Cite as

Antisense depletion of RIα subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells

  • Rakesh K. Srivastava
  • Aparna R. Srivastava
  • Yun Gyu Park
  • Sudhir Agrawal
  • Yoon S. Cho-Chung


In recent years, several laboratories have explored the possibility of using antisense oligodeoxynucleotides for specific manipulation of gene expression leading to cancer treatment. The enhanced expression of the RIα subunit of cyclic AMP-dependent protein kinase type I (PKA-I) has been correlated with cancer cell growth. In the present study, the effects of an antisense oligodeoxynucleotide targeted against RIα subunit of PKA-I on growth inhibition and apoptosis in MDA-MB-231 human breast cancer cells were investigated. The growth inhibitory effects of RIα antisense oligodeoxynucleotide correlated with a decrease in the RIα mRNA and protein levels. The growth inhibition was accompanied by changes in the cell cycle phase distribution, cell morpbology, cleavage of poly (ADP-ribose) polymerase (PARP), and appearance of apoptotic nuclei. By comparison, mismatched control oligodeoxynucleotide had no effect. On the basis of these results, it can be suggested that the RIα antisense oligodeoxynucleotide, which efficiently depletes the growth stimulatory RIα and induces apoptosis/differentiation, could be used as a therapeutic agent for breast cancer treatment.

antisense protein kinase A apoptosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Krebs EG, Beavo JA: Phosphorylation-dephosphorylation of enzymes. Annu Rev Biochem 88: 923–939, 1979Google Scholar
  2. 2.
    Beebe SJ, Corbin JD: Cyclic nucleotide-dependent protein kinases. In: Boyer PD, Krebs EG (eds) The Enzymes: Control by Phosphorylation. Academic Press, New York, 1986, Part A, vol. 17, pp 43–111Google Scholar
  3. 3.
    McKnight GS, Clegg CH, Uhler MD, Chrivia JC, Cadd GG, Correll LA, Otten AD: Analysis of the cAMP dependent protein kinase system using molecular genetic approaches. Recent Prog Horm Res 44: 307–335, 1988Google Scholar
  4. 4.
    Levy FO, Øyen O, Sandberg M, Tasken K, Eskild W, Hansson V, Jahnsen T: Molecular cloning, complementary deoxyribonucleic structure and predicted full-length amino aid sequence of the hormone-inducible regulatory subunit of 3′,5′-cyclic adenosine monophosphate-dependent protein kinase from human testis. Mol Endocrinol 2: 1364–1373, 1988Google Scholar
  5. 5.
    Øyen O, Scott JD, Cadd GG, McKnight GS, Krebs EG, Hansson V, Jahnsen T: A unique mRNA species for a regulatory subunit of cAMP-dependent protein kinase is specifically induced in haploid germ cells. FEBS Lett 229: 391–394, 1988Google Scholar
  6. 6.
    Cadd G, McKnight GS: Distinct patterns of cAMP-dependent protein kinase gene expression in mouse brain. Neuron 3: 71–79, 1989Google Scholar
  7. 7.
    Cadd G, Uhler MD, McKnight GS: Holoenzymes of cAMP-dependent protein kinase containing the neural form of type I regulatory subunit have an increased sensitivity to cyclic nucleotides. J Biol Chem 265: 19502–19506, 1990Google Scholar
  8. 8.
    Lohmann SM, Walter U: Regulation of the cellular and subcellular concentrations and distribution of cyclic nucleotide-dependent protein kinase. Adv Cyclic Nucleotide Protein Phosphorylation Res 18: 63–117, 1984Google Scholar
  9. 9.
    Cho-Chung YS: Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approach to therapy [Perspective in cancer research]. Cancer Res 50: 7093–7100, 1990Google Scholar
  10. 10.
    Schwartz DA, Rubin CS: Identification and differential expression of two forms of regulatory subunits (RII) of cAMP-dependent protein kinase II in Friend erythroleukemic cells. J Biol Chem 260: 6296–6303, 1985Google Scholar
  11. 11.
    Stein CA, Cheng Y-C: Antisense oligonucleotides as therapeutic agents — is the bullet really magical? Science 261: 1004–1012, 1993Google Scholar
  12. 12.
    Wagner RW: Gene inhibition using antisense oligonucleotides. Nature 372: 333–335, 1994Google Scholar
  13. 13.
    Crooke ST: Therapeutic Applications of Oligonucleotides. R.G. Landes Co., Austin, TX, 1995, p 11–38Google Scholar
  14. 14.
    Tortora G, Yokozaki H, Pepe S, Clair T, Cho-Chung YS: Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc Nat Acad Sci USA 88: 2011–2015, 1991Google Scholar
  15. 15.
    Yokozaki H, Budillon A, Tortora G, Meissner S, Beaucage SL, Miki K, Cho-Chung YS: An antisense oligonucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res 53: 868–872, 1993Google Scholar
  16. 16.
    Nesterova M, Cho-Chung YS: A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nat Med 1: 528–533, 1995Google Scholar
  17. 17.
    Zhang R, Lu Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Agrawal S: In vivo stability, disposition and metabolism of a ‘hybrid’ oligonucleotide phosphorothioate in rats. Biochem Pharmacol 50: 545–546, 1995Google Scholar
  18. 18.
    Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, Schulte-Hermann R: Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci USA 89: 5408–5412, 1992Google Scholar
  19. 19.
    Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy-gaps as antisense inhibitors of gene expression. J Biol Chem 268: 14514–14522, 1993Google Scholar
  20. 20.
    Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097–1098, 1991Google Scholar
  21. 21.
    Wyllie AH: Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–307, 1980Google Scholar
  22. 22.
    Schwartz LM, Smith SW, Jones MEE, Osbourne BA: Do all programmed cell deaths occur via apoptosis? Proc Natl Acad Sci USA 90: 980–984, 1993Google Scholar
  23. 23.
    Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539–542, 1994Google Scholar
  24. 24.
    Tortora G, Pepe S, Bianco C, Baldassarre G, Budillon A, Clair T, Cho-Chung YS, Bianco AR, Ciardiello F: The RIα subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene 9: 3233–3240, 1994Google Scholar
  25. 25.
    Gadbois DM, Crissman HA, Tobey RA, Bradbury EM: Multiple kinase arrest points in the G1 phase of nontransformed mammalian cells are absent in transformed cells. Proc Natl Acad Sci USA 89: 8626–8630, 1992Google Scholar
  26. 26.
    Pepe S, Sandomenico C, Damiano V, Ruggiero A, Nesterova M, Bianco AR, Tortora G, Cho-Chung YS: Role of protein kinase A type I (PKAI) in the regulation of HL-60 human promyelocytic leukemia cell cycle kinetics (abstract). Proc Am Assoc Cancer Res 37: 33, 1996Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Rakesh K. Srivastava
    • 1
  • Aparna R. Srivastava
    • 2
  • Yun Gyu Park
    • 1
  • Sudhir Agrawal
    • 3
  • Yoon S. Cho-Chung
    • 1
  1. 1.Cellular Biochemistry Section, Laboratory of Tumor and BiologyNational Cancer Institute, National Institutes of HealthBethesda
  2. 2.Medicine BranchNational Cancer Institute, National Institutes of HealthBethesda
  3. 3.Hybridon, IncCambridgeUSA

Personalised recommendations